title: [A case of a patient with gastric cancer and peritoneal dissemination who survived for more than 10 years after successful treatment with S-1].
abstract: A 50-year-old female patient underwent distal gastrectomy and intraperitoneal CDDP administration for advanced gastric cancer accompanied by severe peritoneal dissemination. She valued her quality of life and chose an oral anticancer drug, S-1, as a postoperative chemotherapy agent. S-1 was administered at a dose of 100mg/body/day for 4 weeks, followed by a 2- week rest. There were no adverse events due to S-1 and no exacerbation of peritoneal dissemination in the 5 years following surgery. The S-1 administration schedule was then changed to alternate-day administration. Eight years after the surgery, the patient discontinued S-1 treatment and has since survived for 11 years with no obvious cancer recurrence.
authors.affiliation: Dept. of Surgery, Omagari Kosei Medical Hospital.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Yamamura
authors.forename: Fuminori
authors.initials: F
authors.lastname: Ono
authors.forename: Masaki
authors.initials: M
authors.lastname: Hiraga
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Omura
authors.forename: Naruhisa
authors.initials: N
authors.lastname: Takano
authors.forename: Hideaki
authors.initials: H
authors.lastname: Sato
authors.forename: Shingo
authors.initials: S
authors.lastname: Toyama
authors.forename: Shoichi
authors.initials: S
authors.lastname: Onochi
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010094:Oxonic Acid / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid